{
    "organizations": [],
    "uuid": "703c27faa36a67d4b73d220d74c0e7bbd4c2658c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-heron-therapeutics-qtrly-net-loss/brief-heron-therapeutics-qtrly-net-loss-per-share-1-09-idUSASB0C7TR",
    "ord_in_thread": 0,
    "title": "BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Heron Therapeutics Inc:\n* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS\n* QTRLY BASIC AND DILUTED NET LOSS PER SHARE $1.09 * QTRLY NET PRODUCT SALES $10.1 MILLION VERSUS $1.3 MILLION\n* Q4 EARNINGS PER SHARE VIEW $-0.79, REVENUE VIEW $9.3 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T06:24:00.000+02:00",
    "crawled": "2018-02-28T13:12:10.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "heron",
        "therapeutic",
        "inc",
        "heron",
        "therapeutic",
        "announces",
        "financial",
        "result",
        "three",
        "twelve",
        "month",
        "ended",
        "december",
        "recent",
        "corporate",
        "progress",
        "qtrly",
        "basic",
        "diluted",
        "net",
        "loss",
        "per",
        "share",
        "qtrly",
        "net",
        "product",
        "sale",
        "million",
        "versus",
        "million",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}